HUP0102975A2 - Kemotaxis-gátló Staphylococcus protein (CHIPS) és annak alkalmazása - Google Patents

Kemotaxis-gátló Staphylococcus protein (CHIPS) és annak alkalmazása

Info

Publication number
HUP0102975A2
HUP0102975A2 HU0102975A HUP0102975A HUP0102975A2 HU P0102975 A2 HUP0102975 A2 HU P0102975A2 HU 0102975 A HU0102975 A HU 0102975A HU P0102975 A HUP0102975 A HU P0102975A HU P0102975 A2 HUP0102975 A2 HU P0102975A2
Authority
HU
Hungary
Prior art keywords
chips
protein
staphylococcus
chemotaxis
relates
Prior art date
Application number
HU0102975A
Other languages
English (en)
Inventor
Cornelis Petrus Maria Van Kessel
Johannes Antonius Gerardus Van Strijp
Original Assignee
Jari Pharmaceuticals B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jari Pharmaceuticals B.V. filed Critical Jari Pharmaceuticals B.V.
Publication of HUP0102975A2 publication Critical patent/HUP0102975A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány kemotaxist gátló hatású Staphylococcus fehérjére és annakbiológiailag aktív fragmenseire vonatkozik, amelyek akut és krónikusgyulladásos reakciók és a HIV fertőzés kezelésében való használatraalkalmasak. A találmány szerinti protein molekulatömege mintegy 17 kD,N-terminális aminosav-szekvenciája az 1. szekvencia és biológiaiaktivitása folytán képes megakadályozni kemotaktikus faktorok,különösen az fMLP és/vagy a C5a megkötődését a granulocitákon. Atalálmány tárgyát képezik olyan gyógyászati készítmények, amelyekgyógyászati szempontból elfogadható vivőanyagok mellett hatóanyagkéntilyen CHIPS proteint tartalmaznak. A találmány tárgyát képezik továbbáaz említett CHIPS proteinek elleni antitestek, valamint az ilyenantitesteket hatóanyagként tartalmazó gyógyászati készítmények,amelyek Staphylococcus fertőzések kezelésére használhatók. Ó
HU0102975A 1998-07-10 1999-07-12 Kemotaxis-gátló Staphylococcus protein (CHIPS) és annak alkalmazása HUP0102975A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1009614 1998-07-10
PCT/NL1999/000442 WO2000002913A1 (en) 1998-07-10 1999-07-12 Chemotaxis-inhibiting protein of staphylococcus (chips) and its use

Publications (1)

Publication Number Publication Date
HUP0102975A2 true HUP0102975A2 (hu) 2001-11-28

Family

ID=19767471

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102975A HUP0102975A2 (hu) 1998-07-10 1999-07-12 Kemotaxis-gátló Staphylococcus protein (CHIPS) és annak alkalmazása

Country Status (22)

Country Link
US (2) US20050143307A1 (hu)
EP (1) EP1095059B1 (hu)
JP (1) JP2002520336A (hu)
KR (1) KR20010053290A (hu)
CN (1) CN1309662A (hu)
AT (1) ATE328898T1 (hu)
AU (1) AU4935999A (hu)
BG (1) BG105120A (hu)
BR (1) BR9911944A (hu)
CA (1) CA2333898A1 (hu)
CY (1) CY1105343T1 (hu)
DE (1) DE69931784T2 (hu)
DK (1) DK1095059T3 (hu)
ES (1) ES2270609T3 (hu)
HU (1) HUP0102975A2 (hu)
IL (1) IL140768A0 (hu)
NO (1) NO20010140L (hu)
NZ (1) NZ509051A (hu)
PL (1) PL345452A1 (hu)
PT (1) PT1095059E (hu)
WO (1) WO2000002913A1 (hu)
ZA (1) ZA200100092B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1309662A (zh) * 1998-07-10 2001-08-22 亚利制药有限公司 葡萄球菌属的趋化性抑制蛋白(chips)及其应用
EP1118663A1 (en) * 2000-01-07 2001-07-25 Universiteit Utrecht Nucleic acids encoding chemotaxis inhibitory polypeptides
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
WO2003006048A1 (en) * 2001-07-11 2003-01-23 Jari Pharmaceuticals B.V. Combination of chips (chemotaxis inhibiting protein from staphylococcus aureus)-based compounds
DE602004031836D1 (de) * 2003-07-08 2011-04-28 Umc Utrecht Holding Bv Therapeutische verwendung von lpi, einem inhibitor des lectinwegs in staphylokokken bei entzündungskrankheiten
EP1586583A3 (en) * 2004-04-16 2005-11-16 Alligator Bioscience AB (publ) Compounds that block C5a complement receptor and their use in therapy
US20090186111A1 (en) 2004-07-26 2009-07-23 Zeev Trainin Novel Bacteria and Pharmaceutically Active Products Obtained Therefrom
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
GB0607798D0 (en) 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772584A (en) * 1986-05-23 1988-09-20 Cleary Paul P Inhibitor of C5a-mediated chemotaxis
AU2509592A (en) * 1991-08-22 1993-03-16 Washington University Polynucleotide probes for salmonella
US5514555A (en) * 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5514455A (en) * 1994-07-08 1996-05-07 Union Carbide Chemicals & Plastics Technology Corporation Film extruded from an in situ blend of ethylene copolymers
US5817476A (en) * 1995-06-07 1998-10-06 Genetics Institute, Inc. Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
CN1309662A (zh) * 1998-07-10 2001-08-22 亚利制药有限公司 葡萄球菌属的趋化性抑制蛋白(chips)及其应用
JP3722194B2 (ja) * 1999-05-20 2005-11-30 セイコーエプソン株式会社 画像表示システム
EP1118663A1 (en) * 2000-01-07 2001-07-25 Universiteit Utrecht Nucleic acids encoding chemotaxis inhibitory polypeptides
US6958213B2 (en) * 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020086292A1 (en) * 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
WO2003097834A2 (en) * 2002-05-17 2003-11-27 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function

Also Published As

Publication number Publication date
BR9911944A (pt) 2001-09-25
NO20010140D0 (no) 2001-01-09
NZ509051A (en) 2003-01-31
JP2002520336A (ja) 2002-07-09
DK1095059T3 (da) 2006-10-02
NO20010140L (no) 2001-03-01
PL345452A1 (en) 2001-12-17
DE69931784T2 (de) 2007-06-14
DE69931784D1 (de) 2006-07-20
AU4935999A (en) 2000-02-01
WO2000002913B1 (en) 2000-03-30
BG105120A (en) 2001-11-30
US20080242605A1 (en) 2008-10-02
CY1105343T1 (el) 2010-03-03
KR20010053290A (ko) 2001-06-25
EP1095059B1 (en) 2006-06-07
IL140768A0 (en) 2002-02-10
ES2270609T3 (es) 2007-04-01
EP1095059A1 (en) 2001-05-02
PT1095059E (pt) 2006-10-31
US20050143307A1 (en) 2005-06-30
ATE328898T1 (de) 2006-06-15
CA2333898A1 (en) 2000-01-20
ZA200100092B (en) 2001-07-23
CN1309662A (zh) 2001-08-22
WO2000002913A1 (en) 2000-01-20

Similar Documents

Publication Publication Date Title
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
DE59905954D1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
ES2130574T3 (es) Agentes de restriccion de las citoquinas.
ATE309271T1 (de) Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen
IL134830A0 (en) Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
ES2163444T3 (es) Composiciones y metodos para la administracion oral de farmacos.
Mitani et al. Suppressive effect on polyclonal B-cell activation of a synthetic peptide homologous to a transmembrane component of oncogenic retroviruses.
RU98120519A (ru) Аутоантиген и структурно-родственные ему белки для применения при иммунотерапии аутоиммунных заболеваний
CY1105008T1 (el) Αντιμικροβιακη ενεργοτητα του πρωτου κατιονικου συγκροτηματος της ανθρωπινης λακτοφερρινης
HUP0001136A2 (hu) Limfatikus tumorok kezelésére szolgáló gyógyszerkészítmények
HUP0102975A2 (hu) Kemotaxis-gátló Staphylococcus protein (CHIPS) és annak alkalmazása
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
RU2001132140A (ru) Рекомбинантный рецептор коллагена на тромбоцитах гликопротеин VI и его применение в фармацевтике
LTIP1753A (en) Dna sequences coding for proteins, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
CA2306441A1 (fr) Peptides issus de gene env du virus de l'immunodeficience feline et leurs applications
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
IL145403A0 (en) Fragments of virus protein 2 or 3 of the polyoma virus, use for transporting active ingredients
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
DK0811068T3 (da) Humane DNase I varianter
RU95105249A (ru) Гидрохлорид ng монометил-l-аргинина, способы его получения, способ получения фармацевтического препарата и способ лечения
FI961505A0 (fi) Uudet veren koaguloitumisjärjestelmässä terapeuttisesti aktiiviset peptidiyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
ATE282704T1 (de) Isolierte und gereinigte humane lösliche guanylylcyclase alpha1/beta1 (hsgc alpha1/beta1)
FR2792639B1 (fr) Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
Ryden Studies on interactions between staphylococcal cells and some connective tissue components.